This site is intended for healthcare professionals
Drug information

Proleukin

POM
Read time: 21 mins
Last updated: 06 May 2020
Published: 01 Apr 2021

4.1 Therapeutic indications

Treatment of metastatic renal cell carcinoma.

Risk factors associated with decreased response rates and median survival are:

- A performance status of ECOG*) 1 or greater

- More than one organ with metastatic disease sites

- A period of < 24 months between initial diagnosis of primary tumour and the date the patient is evaluated for Proleukin treatment.

*) ECOG (Eastern Cooperative Oncology Group) performance status: 0 = normal activity, 1 = symptoms but ambulatory; 2 = in bed less than 50% of time; 3 = in bed more than 50% of time, limited self-care; 4 = completely disabled, no self-care.

Response rates and median survival decrease with the number of risk factors present. Patients positive for all three risk factors should not be treated with Proleukin.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).